(Q38244576)

31 August 2017

DPP-4 inhibitors: pharmacological differences and their clinical implications (English)

1 reference

31 August 2017

1

1 reference

31 August 2017

Concetta Rafaniello

3

0 references

author name string

Liberata Sportiello

series ordinal

2

1 reference

PubMed ID

25171159

31 August 2017

Francesco Rossi

series ordinal

4

1 reference

PubMed ID

25171159

31 August 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

Expert Opinion on Drug Safety

31 August 2017

1 reference

31 August 2017

13 Suppl 1

1 reference

31 August 2017

S57-68

1 reference

Diagnosis and Classification of Diabetes Mellitus

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Fracture risk and bone mineral density in metabolic syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Metabolic syndrome and endometrial cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Cell physiology of cAMP sensor Epac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Postprandial hyperglycemia and glycemic variability: should we care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

The glucose triad and its role in comprehensive glycaemic control: current status, future management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Postprandial glucose regulation and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Oxidative stress and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Cardiovascular effects of gliptins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.944862

10.1517/14740338.2014.944862

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25171159